James E. Brown

Selected news for the person - James E. Brown, collected since 11/2017. Recent stories appear in PR Newswire. This person shares healthcare news with Food and Drug Administration and Gilead.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics
Companies

Selected Headlines

Date Headline (link) Source Relevant Snippet
6/23/2021 DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) PR Newswire ... International Liver Conference (EASL) being held virtually June 23-26, 2021."We are pleased to report additional signals of potential efficacy from our Phase 1b NASH trial of DUR-928, our lead epigenetic regulator," said James E. Brown , D.V.M., President and CEO of DURECT. "The roughly 20% median reduction from baseline of HOMA-IR, an important indicator of insulin resistance, observed after only 4 weeks of daily oral administration at the ...
6/23/2021 DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) PR Newswire ... International Liver Conference (EASL) being held virtually June 23-26 , 2021."We are pleased to report additional signals of potential efficacy from our Phase 1b NASH trial of DUR-928, our lead epigenetic regulator," said James E. Brown , D.V.M., President and CEO of DURECT. "The roughly 20% median reduction from baseline of HOMA-IR, an important indicator of insulin resistance, observed after only 4 weeks of daily oral administration at the ...
2/12/2021 The Complicated Legacy of James E. Brown (c. 1802–1853), Liberian Colonial Apothecary pointshistory.com ... and other items of interest from AIHP publications and collections. In honor of Black History Month, Points Managing Editor Greg Bond revisits his two-part 2018 Pharmacy in History article about Liberian Colonial Apothecary James E. Brown. Read the full articles ( Part 1 and Part 2 ) at JSTOR. Colonial Apothecary James Brown’s 1834 advertisement in the Liberia Herald as reprinted in The African Repository , September 1834.In the May ...
2/10/2021 International ABB leader to head ABB's Machine Automation DivisionB&R under new management: ABB appoints Jörg Theis as CEO industry24h.com ... working with this highly motivated and talented team. We have confidence that Evonik will apply its resources and commitment to excellence to enable their product line and supporting team members to thrive,” says James E. Brown , President and Chief Executive Officer. With their global reach, existing and new customers will benefit from tapping into Health Care’s twelve global laboratories staffed with formulation, application and regulatory experts to assist ...
2/3/2021 Cooperation between Lactel and Evonik industry24h.com ... working with this highly motivated and talented team. We have confidence that Evonik will apply its resources and commitment to excellence to enable their product line and supporting team members to thrive,” says James E. Brown , President and Chief Executive Officer. With their global reach, existing and new customers will benefit from tapping into Health Care’s twelve global laboratories staffed with formulation, application and regulatory experts to assist ...
2/2/2021 Durect (DRRX) Receives a Buy from B.Riley Financial markets.co ... includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA ...
1/5/2021 DURECT Corporation Appoints Two New Board Members salesandmarketingnetwork.com ... development, clinical research and medical affairs experience. "We are pleased to welcome Ms. Maderis and Dr. Azab to our board as we continue to enhance our board in line with our maturing company," stated James E. Brown , D.V.M., President and Chief Executive Officer of DURECT. "Their extensive expertise will be valuable as we continue to advance our clinical pipeline and create value for our shareholders, in particular as we advance ...
9/22/2020 DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM) PR Newswire ... Company is targeting 40-45 clinical trial sites in the US and Europe and anticipates trial initiation in October. "We are pleased to announce the design and pending initiation of this important clinical trial," stated James E. Brown , D.V.M., President and CEO of DURECT. "Following on the very encouraging results from our Phase 2a AH trial, we believe that the Phase 2b AHFIRM trial will provide a robust evaluation of the ...
8/27/2020 DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL) PR Newswire ... was well tolerated at all doses tested in AH patients and contributed to the dose selection in our upcoming Phase 2b AH trial, which we look forward to initiating in the upcoming months," stated James E. Brown , D.V.M., President and CEO of DURECT. About the DUR-928 Alcoholic Hepatitis Phase 2a Trial This open-label, dose escalation, multi-center study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics ...
8/5/2020 DURECT to Present at the BTIG Biotechnology Conference 2020 PR Newswire DURECT to Present at the BTIG Biotechnology Conference 2020 News provided by Aug 05, 2020, 08:30 ET Share this article CUPERTINO, Calif. , Aug. 5, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX ) announced today that James E. Brown , President and CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August ...
8/5/2020 DURECT to Present at the BTIG Biotechnology Conference 2020 BioSpace CUPERTINO, Calif. , Aug. 5, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT . Institutional investors that are participating in the conference may request a ...
8/5/2020 DURECT to Present at the BTIG Biotechnology Conference 2020 vporoom.com News Releases DURECT to Present at the BTIG Biotechnology Conference 2020 CUPERTINO, Calif. DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT . Institutional investors that are ...
8/5/2020 DURECT to Present at the BTIG Biotechnology Conference 2020 gurufocus.com PR Newswire CUPERTINO, Calif., Aug. 5, 2020 CUPERTINO, Calif. , DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , President and CEO, Michael H. Arenberg , Chief Financial Officer and Dr. WeiQi Lin , Executive Vice President of R&D will be participating in a fireside chat at the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m. PDT . Institutional investors that are participating in the conference ...
8/4/2020 Durect Corp (DRRX) Q2 2020 Earnings Call Transcript | The Motley Fool fool.com DRRX earnings call for the period ending June 30, 2020. Aug 4, 2020 at 1:00AM Image source: The Motley Fool. Aug 3, 2020 , 4:30 p.m. ET Contents: Prepared Remarks: Operator Greetings, and welcome to the Durect Corporation Second Quarter 2020 Earnings Conference Call. [Operator Instructions] As a reminder this conference is being recorded. I would now like to turn the conference over to your host, Mr. Mike Arenberg, Chief Financial ...
8/3/2020 DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs PR Newswire ... the second quarter. We were pleased to report positive topline data from our Phase 1b NASH trial and we look forward to presenting additional data from the trial at a future scientific meeting," stated James E. Brown , D.V.M., President and CEO of DURECT. "We also initiated a Phase 2 trial of DUR-928 in COVID-19 patients with acute liver or kidney injury and are finalizing our preparations to initiate ...
8/3/2020 DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs gurufocus.com ... the second quarter. We were pleased to report positive topline data from our Phase 1b NASH trial and we look forward to presenting additional data from the trial at a future scientific meeting," stated James E. Brown , D.V.M., President and CEO of DURECT. "We also initiated a Phase 2 trial of DUR-928 in COVID-19 patients with acute liver or kidney injury and are finalizing our preparations to initiate ...
7/23/2020 Sanitation Best Practices: What Can Hotels Learn from Hospitals? hospitalitytech.com ... of advice. To begin with, not every product labeled as a disinfectant is considered effective against COVID-19. “It is very important to select the proper disinfectant that is effective against COVID-19,” says James E. Brown , MHA, Director of Environmental Services at Deborah Heart and Lung Center , New Jersey’s only specialty heart, lung and cardiac hospital, and an Alliance Partner at the Cleveland Clinic Heart, Vascular & Thoracic Institute. “It ...
7/1/2020 DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury PR Newswire ... our preclinical data in multi-organ failure models, we believe that DUR-928, in combination with standard of care, has the potential to help COVID-19 patients with acute liver or kidney injury," stated James E. Brown , D.V.M., President and CEO of DURECT. "There is a great need to explore life-saving treatment options for these high risk patients." About the Phase 2 Trial This Phase 2, randomized, double-blind ...
5/28/2020 DURECT to Present at the Jefferies 2020 Virtual Health Care Conference PR Newswire CUPERTINO, Calif. DURECT Corporation (Nasdaq: DRRX ) announced today that James E. Brown , President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference, Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m. PDT . Institutional investors and analysts that are participating in the conference may request a virtual one-on-one meeting through the conference coordinators. A live audio webcast of the presentation will be available by ...
3/3/2020 DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs PR Newswire ... positive results from our DUR-928 Phase 2a alcoholic hepatitis (AH) study, which were featured in multiple presentations at the Liver Meeting ® 2019, including a late-breaking oral presentation by Dr. Tarek Hassanein ," stated James E. Brown , D.V.M., President and CEO of DURECT. "In addition, we have already exceeded our 60 patient enrollment target in the ongoing NASH trial, and the last patient is scheduled to begin the 28-day ...